Small- and mid-sized biotechs can avoid the “big pharma trap” as they scale from R&D to commercialisation by building proportionate, risk-based compliance frameworks. Some biotechs overcorrect by copying large-company SOPs, adding bureaucracy, and implementing global-style frameworks that don’t match their size/stage of development. This leads to frustration and workarounds . Regulators do not expect small biotechs to mirror “big pharma”. All biotech and pharma companies, whatever their size operate under the same regulatory framework. Organisations are expected to demonstrate evidence of proportionate control, accountability, and risk awareness, aligned to their size, activities, and stage of development. The goal isn’t to “become big pharma,” but to become commercially ready; ready for scrutiny, growth, and accountability, using a pragmatic, maturity-led approach.

Many biotech organisations assume the transition from R&D to commercial is gradual, but in reality it represents a step change in healthcare compliance expectations. Codes such as ABPI, EFPIA, IFPMA and PhRMA apply well before product launch, with obligations triggered by pre‑commercial and market‑facing activity rather than organisational maturity. This article explores the key compliance risks that face R&D‑led organisations as they transition to commercial, including scientific exchange, HCP interactions, patient engagement and transparency, and explains what “commercial‑ready compliance” really looks like for biotechs preparing for their first launch.

AI is already transforming pharma and biotech, but adoption is outpacing governance. This insight explores where AI genuinely adds value, where compliance risk escalates, and why a risk‑based governance approach led by senior leaders is essential to enable innovation without losing regulatory control.

During a pivotal period at a major pharma manufacturing site facing closure, teams were tasked with maintaining uninterrupted supply, safeguarding quality standards, and protecting patient safety while operations transitioned elsewhere. With only 18 months to deliver, the organisation needed clarity, discipline, and a shared approach to doing the right thing under pressure. From that challenge emerged a simple, memorable framework which remains widely applicable today: The ABC of Compliance. This leadership model helps organisations strengthen culture, design out risk, and respond effectively when issues arise. It provides a practical anchor for leaders who want to build confidence, consistency, and accountability across their teams.

In the pharmaceutical sector, social media activity by employees can carry significant compliance risks. This article outlines key dos and don’ts, including the dangers of reposting promotional content, engaging with third-party posts, and discussing prescription-only medicines online. With global regulations in mind, it introduces a simple framework, Restrict, Report, Regionalise, to help employees navigate digital platforms responsibly and protect both personal and organisational integrity.

This article explores the strategic dilemma Boards face in categorising cybersecurity and artificial intelligence risks within governance frameworks. As regulatory pressure and technological complexity increase, the way these risks are "labelled" significantly impacts Board oversight. Boards must choose between elevating cyber and AI to standalone strategic risks (increasing visibility and accountability) or integrating them as sub-risks of information governance (ensuring a holistic view of the data lifecycle).